Head-to-Head
Peptide comparisons, by the evidence
Independent side-by-side comparisons: which compound the research favors, for whom, and where the honest caveats are.
Semaglutide vs Tirzepatide
AFDA-ApprovedvsAFDA-Approved
Tirzepatide produced larger weight loss in trials (up to ~21% vs ~15%); semaglutide has the longer cardiovascular-outcomes record and an oral option. An independent, evidence-based comparison.
BPC-157 vs TB-500
DPreclinical OnlyvsCEmerging Human Data
Both are popular recovery peptides with strong animal data and little human evidence. TB-500's parent peptide reached early human trials (Grade C) versus BPC-157's Grade D. Neither is FDA-approved.